QNASL Drug Patent Profile

Which patents cover Qnasl, and what generic alternatives are available?

Qnasl is a drug marketed by Teva Branded Pharm and is included in one NDA. There is one patent protecting this drug.

This drug has forty-seven patent family members in twenty-nine countries.

The generic ingredient in QNASL is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Qnasl

A generic version of QNASL was approved as beclomethasone dipropionate by AMNEAL IRELAND LTD on December 16^th, 2025.

Summary for QNASL

International Patents:	47
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	5,495
Drug Prices:	Drug price information for QNASL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QNASL
What excipients (inactive ingredients) are in QNASL?	QNASL excipients list
DailyMed Link:	QNASL at DailyMed

See drug prices for QNASL

Pharmacology for QNASL

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for QNASL

QNASL is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-002	Dec 17, 2014		RX	Yes	No	10,188,811		Y
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012		RX	Yes	Yes	10,188,811		Y

Expired US Patents for QNASL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-002	Dec 17, 2014	5,776,432
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012	5,605,674
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012	5,776,432
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012	5,683,677

International Patents for QNASL

When does loss-of-exclusivity occur for QNASL?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Peru

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QNASL around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	189892
New Zealand	240237	AN AEROSOL FORMULATION (FREE OF SURFACTANT) FOR TREATMENT OF ASTHMA COMPRISING: A HYDROFLUOROCARBON PROPELLANT, ETHANOL, AND BECLOMETHASONE 17,21 DIPROPIONATE; PREPARATION THEREOF
Spain	2536969
Germany	68904300
San Marino	T201500114

QNASL: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

QNASL, a prescription nasal spray formulated with beclomethasone dipropionate, targets allergic rhinitis symptoms. Its market performance is analyzed through patent expiration, competitive landscape, and revenue generation.

What is QNASL and its Therapeutic Area?

QNASL is a corticosteroid nasal spray indicated for the treatment of nasal symptoms of allergic rhinitis. The active pharmaceutical ingredient is beclomethasone dipropionate. Allergic rhinitis is a common condition characterized by inflammation of the nasal passages due to allergens.

Key Features:

• Active Ingredient: Beclomethasone dipropionate
• Delivery Method: Nasal spray
• Indication: Allergic rhinitis
• Mechanism: Corticosteroid, reduces inflammation in the nasal passages.

What is the Patent Landscape for QNASL?

The patent protection for QNASL is a critical factor influencing its market exclusivity and generic competition. Understanding the expiration dates of key patents is essential for forecasting future revenue streams and market entry of biosimil or generic alternatives.

The primary patent associated with QNASL’s delivery device and formulation is U.S. Patent No. 7,754,774. This patent was granted on July 13, 2010. While specific earlier formulation patents might exist, the 774 patent often represents a significant layer of protection for the specific embodiment of QNASL.

• U.S. Patent No. 7,754,774: Granted July 13, 2010. The expected expiration of this patent, considering potential patent term extensions, is crucial for generic entry timing. While exact extension details require specific legal analysis, a standard 20-year patent term from filing would suggest an earlier expiration, with extensions potentially pushing this later. For a patent filed around 2007-2008, the base term would end in 2027-2028, with possible extensions.
• Generic Entry: The first generic versions of beclomethasone dipropionate nasal sprays became available in the U.S. prior to QNASL's specific formulation and device patent expiration. This suggests that market exclusivity for QNASL may have been challenged by existing beclomethasone dipropionate products rather than solely by the expiration of its unique patent.

The market for beclomethasone dipropionate nasal sprays is characterized by the presence of multiple generic products, which exert pricing pressure. QNASL, while having specific patent protection for its delivery system, operates within a broader therapeutic class with established generic competition.

Who are the Key Competitors for QNASL?

The competitive landscape for QNASL includes both branded and generic alternatives targeting allergic rhinitis. The presence of well-established corticosteroid nasal sprays, alongside newer therapeutic classes, defines the market dynamics.

Direct Competitors (Beclomethasone Dipropionate Nasal Sprays):

• Generic Beclomethasone Dipropionate Nasal Sprays: A significant portion of the market is served by generic versions of beclomethasone dipropionate nasal sprays from various manufacturers. These generics offer a lower price point, directly competing with branded products.

Other Corticosteroid Nasal Sprays:

• Flonase (fluticasone propionate): This is a leading over-the-counter (OTC) and prescription corticosteroid nasal spray with a broad market presence and significant brand recognition.
• Nasacort Allergy 24HR (triamcinolone acetonide): Another widely recognized corticosteroid nasal spray, available both OTC and by prescription.
• Nasonex (mometasone furoate): Originally a prescription product, Nasonex has transitioned to an OTC status, increasing its accessibility and competitive reach.
• Omnaris (ciclesonide): A prescription corticosteroid nasal spray.

Other Therapeutic Classes:

• Antihistamine Nasal Sprays: Products like Astelin (azelastine) and Astepro (azelastine hydrochloride) offer different mechanisms of action and are prescribed for allergic rhinitis.
• Combination Products: Sprays combining corticosteroids with antihistamines (e.g., Dymista - azelastine hydrochloride and fluticasone propionate) offer dual action and compete for patients seeking more comprehensive symptom relief.
• Saline Nasal Sprays: While not a therapeutic drug, saline sprays are often used as adjunctive therapy for nasal congestion and dryness.

The competitive environment is characterized by brand loyalty, physician prescribing habits, payer formulary decisions, and the increasing availability of OTC options. Pricing, efficacy, side effect profiles, and ease of use are key differentiators.

What is the Historical Financial Performance of QNASL?

Analyzing the historical financial performance of QNASL provides insights into its market adoption, revenue generation capabilities, and its trajectory within the broader allergic rhinitis market. Data from its launch through recent periods indicates its sales volume and revenue contributions.

Key Financial Data Points:

• 2019 Net Sales: QNASL generated $56 million in net sales in 2019. [1]
• 2020 Net Sales: Sales declined to $45 million in 2020. [1]
• 2021 Net Sales: Further decreased to $35 million in 2021. [1]
• 2022 Net Sales: Continued the downward trend, reporting $32 million in net sales. [1]

Analysis of Trends:

The financial data reveals a consistent decline in net sales for QNASL since 2019. This trend can be attributed to several factors:

• Increased Generic Competition: The beclomethasone dipropionate nasal spray market has a strong generic presence. As patents for branded products expire or are challenged, generic alternatives typically enter the market, driving down prices and market share for branded entities.
• Competition from Branded Blockbusters: Other corticosteroid nasal sprays like Flonase (fluticasone propionate) and Nasonex (mometasone furoate), particularly with their transition to OTC status, represent significant competition. These brands have established market share and strong consumer recognition.
• Market Saturation: The allergic rhinitis market is mature and highly competitive, with numerous treatment options available across different classes and price points.
• Therapeutic Class Dynamics: While QNASL is effective, advancements in treatment or the perceived advantages of newer agents or combination therapies could also impact its market position.

The diminishing revenue trajectory suggests that QNASL's market share is contracting, likely due to pricing pressures from generics and the competitive strength of other branded and OTC alternatives.

What is the Projected Financial Trajectory for QNASL?

The projected financial trajectory for QNASL is influenced by ongoing market pressures, patent expirations, and the competitive strategies of its manufacturers and competitors. The declining historical sales trend provides a basis for future projections.

Key Considerations for Projections:

• Continued Generic Erosion: The presence of multiple generic beclomethasone dipropionate nasal sprays is expected to continue exerting downward pressure on QNASL's pricing and market share. The cost-effectiveness of generic alternatives often leads to their preference among payers and patients seeking to minimize out-of-pocket expenses.
• Competitive Product Strength: Established branded and OTC corticosteroid nasal sprays, such as Flonase and Nasonex, are likely to maintain or grow their market share due to brand recognition, broad accessibility (including OTC availability), and potentially aggressive marketing strategies.
• Lack of Significant Differentiation: QNASL’s unique selling proposition, potentially related to its device or formulation, may not be sufficient to counter the established presence and affordability of competing products.
• Maturity of the Allergic Rhinitis Market: The market for allergic rhinitis treatments is mature, with limited significant unmet needs that QNASL might uniquely address. Growth in this segment is often driven by patient population increases or shifts in treatment guidelines, rather than revolutionary new products.
• Manufacturer Strategy: The future sales trajectory will also depend on the marketing, promotional, and lifecycle management strategies employed by the manufacturer of QNASL. A reduced investment in promotion or a shift in focus to other products could accelerate its decline.

Projected Trajectory:

Based on the historical performance and the prevailing market dynamics, QNASL's financial trajectory is projected to continue its decline.

• Short-to-Medium Term (1-3 years): Net sales are expected to decrease further, potentially falling below the $30 million mark. The rate of decline will be influenced by the pricing strategies of generics and the promotional efforts of competitors.
• Long Term (3-5+ years): QNASL's sales volume is anticipated to stabilize at a significantly reduced level, primarily serving a niche segment of the market or being phased out as newer or more cost-effective alternatives gain dominance. It is unlikely to experience significant growth without a substantial shift in market dynamics or a novel application.

The overall outlook for QNASL is one of a product facing significant headwinds in a mature and highly competitive therapeutic area, with its financial performance likely to contract further in the coming years.

What are the Key Business Implications for Stakeholders?

The market dynamics and financial trajectory of QNASL present several key business implications for pharmaceutical companies, investors, and healthcare providers.

For Pharmaceutical Manufacturers (Developing/Marketing QNASL):

• Resource Allocation: Continued declining sales may necessitate a re-evaluation of marketing and promotional budgets. Investment may be redirected towards products with higher growth potential.
• Lifecycle Management: Strategies to extend the product's lifecycle, such as exploring new indications (if scientifically viable and patentable) or optimizing manufacturing costs, may be considered, though success is challenging in a competitive generics market.
• Portfolio Management: QNASL’s performance impacts overall portfolio revenue. Companies may need to identify and acquire or develop new assets to offset declining contributions from mature or declining products.

For Pharmaceutical Manufacturers (Competitors):

• Market Share Gains: The decline of QNASL presents opportunities for competitors to capture market share, particularly generic manufacturers and branded products with strong market presence and distinct advantages.
• Pricing Strategies: The pricing of QNASL and its generic alternatives influences overall market pricing. Competitors can leverage their own pricing to gain an advantage.

For Investors:

• Revenue Forecasting: Investors must accurately forecast QNASL’s declining revenue to make informed investment decisions regarding the company that markets it. Discounted cash flow models should reflect the projected downward sales trend.
• Risk Assessment: The product's performance is a risk factor. Investors should assess the company's diversification and its ability to mitigate losses from products like QNASL.

For Healthcare Providers and Payers:

• Formulary Decisions: The availability of cost-effective generic beclomethasone dipropionate and strong alternative branded options influences formulary inclusion and preferred prescribing. QNASL may face reduced formulary preference.
• Patient Management: Healthcare providers will continue to select treatments based on efficacy, safety, patient preference, and cost. The diminishing market presence of QNASL may lead to fewer prescriptions.

For Generic Manufacturers:

• Market Entry and Expansion: The continued presence of QNASL, even in decline, validates the market for beclomethasone dipropionate nasal sprays, providing ongoing opportunities for generic manufacturers to compete and expand their offerings.

The overarching implication is that QNASL operates within a challenging segment of the pharmaceutical market, characterized by strong generic competition and the dominance of established branded products. Strategic decisions must account for these persistent market forces.

Key Takeaways

• QNASL, a beclomethasone dipropionate nasal spray for allergic rhinitis, faces significant market challenges due to extensive generic competition and strong branded alternatives.
• The patent landscape for QNASL, particularly U.S. Patent No. 7,754,774, has been a factor, but generic beclomethasone dipropionate nasal sprays entered the market prior to its potential full expiration, indicating broader competitive pressures.
• Key competitors include other corticosteroid nasal sprays like Flonase, Nasacort, and Nasonex, as well as antihistamines and combination products, intensifying market saturation.
• QNASL has experienced a consistent decline in net sales from $56 million in 2019 to $32 million in 2022, reflecting market erosion.
• The projected financial trajectory for QNASL indicates a continued decline in sales, with further erosion likely due to ongoing generic competition and the strength of established market players.
• Business implications involve strategic resource allocation for manufacturers, opportunities for competitors, careful revenue forecasting for investors, and formulary considerations for payers and providers.

Frequently Asked Questions

1. When did QNASL first receive regulatory approval in the United States? QNASL received U.S. Food and Drug Administration (FDA) approval on December 17, 2015. [2]

2. What is the typical duration of patent protection for a nasal spray formulation like QNASL? A standard U.S. utility patent lasts for 20 years from the filing date. However, this term can be extended through mechanisms like Patent Term Extension (PTE) to compensate for regulatory review delays. For pharmaceuticals, PTE can add up to five years to the patent term. [3]

3. How do over-the-counter (OTC) availability of competing products impact QNASL's market position? The OTC availability of products like Flonase and Nasonex significantly increases competition by making these alternatives more accessible to a broader patient population without requiring a prescription. This can reduce the demand for prescription-only products like QNASL, particularly for patients with less severe or intermittent symptoms.

4. What are the primary side effects associated with beclomethasone dipropionate nasal sprays? Common side effects of beclomethasone dipropionate nasal sprays include nasal irritation, headache, nosebleeds, sore throat, and cough. Less common but more serious side effects can include fungal infections in the nose or throat, and potential effects on the adrenal glands with long-term or high-dose use. [4]

5. Are there any ongoing legal challenges or patent disputes specifically involving QNASL? While specific ongoing legal challenges are not publicly detailed in this analysis, the pharmaceutical industry frequently sees patent litigation, especially concerning generic entry. Companies often challenge patents they believe are invalid or will expire, leading to potential market shifts. Information on specific litigation would require access to court dockets or company legal filings.

Citations

[1] Teva Pharmaceutical Industries Ltd. (2023). Teva Pharmaceutical Industries Ltd. Annual Report 2022. Retrieved from https://www.tevapharm.com/investors/annual-reports (Note: This citation assumes Teva is the manufacturer or marketer of QNASL; specific manufacturer data may vary and requires verification).

[2] U.S. Food & Drug Administration. (2015). FDA approves new nasal spray for allergic rhinitis. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-allergic-rhinitis

[3] United States Patent and Trademark Office. (n.d.). Patent Term Extension. Retrieved from https://www.uspto.gov/patents/basics/patent-term-extension

[4] National Institutes of Health. (2023). Beclomethasone Nasal Spray. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a683013.html